Award
National Cancer Institute 1R01CA298151-01A1
Deciphering the role of MLL-partial tandem duplication in AML through integrated genomic and proteomic approaches
Recipient
University of Wisconsin-Madison
Award Amount
$699,587.00
Ceiling
$699,587.00
Awarded
July 21, 2026
Identifier
1R01CA298151-01A1
This NIH grant awarded by the National Cancer Institute supports research to elucidate how MLL-partial tandem duplication influences leukemia development and progression, aiming to develop targeted therapies for AML and MDS.
Description
The project focuses on understanding the mechanism by which MLLPTD drives disease progression in AML. It involves proteomic, transcriptomic, and epigenomic technologies. The award is multi-year, starting August 1, 2026, and ending July 31, 2031. The project is significant for developing targeted therapies for AML and MDS.